For the treatment of partial onset seizures there is a greater prevalence of data research pointing toward biologics or various forms of brain wave stimulation or modulation.
There not any published studies available comparing Pharmacotherapy to device products.
There are studies adding an antiseizure medicine post Neurostimulation treatment with some additive effects. The numbers are small and anecdotal in conclusion.
Would combination therapy be possible? It could, but the patient cannot be on an anti-seizure medicine while receiving Neurostimulation.
The alternative is the current status…generic medicines first…brand products or a device next with improvement depending on the severity of the seizures.
The solution? Targeted gene therapy? It has been studied for the past 15 years without market introduction.
Is the gene therapy worth the investment?
If only marginally better, then given the expected cost for gene therapy, it will not be widely used.
The product needs to be given one time or at least once per month. It has to be delivered orally as there are so many limitations to intrathecal or intravenous products. Also, most importantly, it needs efficacy better than 22% seizure freedom.
There are ways to introduce a biologic or genetic product into the Epilepsy market. If you would like to discuss more on this topic for commercialization suggestions, contact us.
